ArticleGastrointestinal endoscopy2015
Recurrent intestinal metaplasia after radiofrequency ablation for Barrett's esophagus: endoscopic findings and anatomic location.
Article in Gastrointestinal endoscopy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Guideline
- Risk of recurrence of Barrett's esophagus after successful endoscopic therapy.Gastrointestinal endoscopy · 2016Pooled it
- Review
- Risk stratification for synchronous/metachronous recurrence after endoscopic submucosal dissection for Barrett's esophageal adenocarcinoma using the length of Barrett's esophagus.Esophagus : official journal of the Japan Esophageal Society · 2024Article
- Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.Current treatment options in gastroenterology · 2023Review
- Outcomes of Radiofrequency Ablation Compared to Liquid Nitrogen Spray Cryotherapy for the Eradication of Dysplasia in Barrett's Esophagus.Digestive diseases and sciences · 2022Article
- A cost-effectiveness modeling study of treatment interventions for stage I to III esophageal squamous cell carcinoma.Cost effectiveness and resource allocation : C/E · 2022Article
- A Pilot Study on Automatic Three-Dimensional Quantification of Barrett's Esophagus for Risk Stratification and Therapy Monitoring.Gastroenterology · 2021Article
- Cryoballoon ablation for treatment of patients with refractory esophageal neoplasia after first line endoscopic eradication therapy.Endoscopy international open · 2020Article
- Management of Barrett Esophagus Following Radiofrequency Ablation.Gastroenterology & hepatology · 2019Article
- Durability of Endoscopic Treatment for Dysplastic Barrett's Esophagus.Current treatment options in gastroenterology · 2019Review
- Challenges in Endoscopic Therapy of Dysplastic Barrett's Esophagus.Current treatment options in gastroenterology · 2019Review
- Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells.Gastroenterology · 2019Article
- Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.Digestive diseases and sciences · 2018Review
- Natural History of the Post-ablation Esophagus.Digestive diseases and sciences · 2018Review
- Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus.Gastroenterology · 2018Observational
- Cryotherapy and Radiofrequency Ablation for Eradication of Barrett's Esophagus with Dysplasia or Intramucosal Cancer.Digestive diseases and sciences · 2018Article
- Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium.The American journal of gastroenterology · 2017Review
- Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis.Endoscopy international open · 2017Article
- Quality Indicators in Endoscopic Ablation for Barrett's Esophagus.Current treatment options in gastroenterology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRadiofrequency ablation (RFA) is a safe and effective treatment for Barrett's esophagus (BE) that results in high rates of complete eradication of intestinal metaplasia (CEIM). However, recurrence is common after CEIM, and surveillance endoscopy is recommended. Neither the anatomic location nor the endoscopic appearance of these recurrences is well-described.
objectiveDescribe the location of histologic specimens positive for recurrence after CEIM and the testing performance of endoscopic findings for the histopathologic detection of recurrence.
designRetrospective cohort.
settingSingle referral center. PATIENTS: A total of 198 patients with BE with at least 2 surveillance endoscopies after CEIM.
interventionsRFA, EMR, surveillance endoscopy. MAIN OUTCOME MEASUREMENTS: The anatomic location and histologic grade of recurrence.
resultsIn a mean 3.0 years of follow-up, 32 (16.2%; 95% confidence interval [CI], 11.0%-22.0%) patients had recurrence of disease, 5 (2.5%; 95% CI, 0.3%-4.7%) of whom progressed beyond their worst before-treatment histology. Recurrence was most common at or near the gastroesophageal junction (GEJ). Recurrence>1 cm proximal to the GEJ always was accompanied by endoscopic findings, and random biopsies in these areas detected no additional cases. The sensitivity of any esophageal sign under high-definition white light or narrow-band imaging for recurrence was 59.4% (42.4%, 76.4%), and the specificity was 80.6% (77.2%, 84.0%). LIMITATIONS: Single-center study.
conclusionRecurrent intestinal metaplasia often is not visible to the endoscopist and is most common near the GEJ. Random biopsies>1 cm above the GEJ had no yield for recurrence. In addition to biopsy of prior EMR sites and of suspicious lesions, random biopsies oversampling the GEJ are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.